Download PDF
Klin Monbl Augenheilkd 2012; 229(5): 529-533
DOI: 10.1055/s-0031-1299523
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Bakterielle Konjunktivitis – Update zu Diagnose und Therapie

Bacterial Conjunctivitis – Diagnosis and Therapy Update
E. M. Messmer
Further Information

Publication History

15 March 2012

22 March 2012

Publication Date:
16 May 2012 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die akute bakterielle Konjunktivitis ist ein häufiges Problem sowohl in der Allgemeinarztpraxis als auch beim Ophthalmologen. Die Symptome und klinischen Zeichen erlauben meist eine Diagnose ohne Bindehautabstrich. Mikrobiologische Untersuchungen werden primär bei Neugeborenen, Immunsupprimierten und hyperakuter Konjunktivitis empfohlen. Besorgniserregend ist die zunehmende Isolierung methicillinresistenter Staph. aureus in den letzten Jahren. Studien belegen die schnellere klinische und mikrobielle Remission der bakteriellen Konjunktivitis unter antibiotischer Lokaltherapie. Die zunehmende Resistenzentwicklung der klassischen Konjunktivitiserreger gegenüber allen Antibiotikagruppen ist jedoch alarmierend und sollte das Therapieverhalten beeinflussen. Fluoroquinolone sind in der Therapie der akuten bakteriellen Konjunktivitis sehr gut wirksam, müssen jedoch aufgrund ihres effizienten Wirkspektrums als Reservemedikament in der Therapie der akuten Konjunktivitis gelten. Antibiotika wie Gentamycin, Tobramicin und Azithromycin sollte der Vorzug gegeben werden. Bei hoher Spontanheilungsrate ist auch eine verzögerte Antibiotikagabe bei Persistenz der Beschwerden nach 3 – 4 Tagen bzw. eine Therapie ohne Antibiose mit Tränenersatz und Augenbädern zu erwägen. Eine additive antientzündliche Therapie wird generell nicht empfohlen. Eine chronisch rezidivierende follikuläre Konjunktivitis erfordert einen Chlamydienabstrich und, bei positivem Nachweis, eine systemische Antibiose von Patient und Sexualpartner.

Abstract

Acute bacterial conjunctivitis is a common health-care issue for the general practitioner and the ophthalmologist. Signs and symptoms usually allow a correct diagnosis without conjunctival swab. Primary microbiological investigations are recommended in newborns, immunocompromised patients and cases of hyperacute conjunctivitis. Of concern are methicillin-resistant Staphylococcus aureus strains which have been isolated with increasing frequency in the last few years. Studies have demonstrated the faster clinical and microbiological cure of acute bacterial conjunctivitis with topical antibiotics. However, the development of resistance of the typical germs to all of the antibiotic groups is alarming and should influence therapeutic behaviour. Fluoroquinolones show good activity in the treatment of acute bacterial conjunctivitis but should be saved for severe infections due to its broad spectrum of activity. Antibiotics such as gentamycin, tobramycin, and azithromycin should be preferred. Considering the high spontaneous healing rate of acute conjunctivitis, delayed topical antibiotics in case of persistence after 3 – 4 days, or treatment without antibiotics using artificial tears and eye bathings may be considered. Additive anti-inflammatory drugs are generally not recommended. Chronic-recurrent follicular conjunctivitis necessitates testing for Chlamydia, and in case of a positive result, systemic antibiotic treatment of patient and sexual partner.

Schlüsselwörter

Bindehaut - Infektiologie - Mikrobiologie

Key words

conjunctiva - infectious diseases - microbiology
 

  • Literatur

  • 1 Smith AF, Waycaster C. Estimate of the direct and indirect annual cost of bacterial conjunctivitis in the United States. BMC Ophthalmol 2009; 9: 13
    CrossrefPubMedGoogle Scholar
  • 2 Weiss A, Brinser JH, Nazar-Stewart V. Acute conjunctivitis in childhood. J Pediatr 1993; 122: 10-14
    CrossrefPubMedGoogle Scholar
  • 3 Gigliotti F, Williams WT, Hayden FG et al. Etiology of acute conjunctivitis in children. J Pediatr 1981; 98: 531-536
    CrossrefPubMedGoogle Scholar
  • 4 Lichtenstein SJ, Rinehart M. Efficacy and safety of 0.5% levofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis in pediatric patients. J AAPOS 2003; 7: 317-324
    PubMedGoogle Scholar
  • 5 Dart JK. Eye disease at a community health centre. Br Med J (Clin Res Ed) 1986; 293: 1477-1480
    PubMedGoogle Scholar
  • 6 McDonnell PJ. How do general practitioners manage eye disease in the community?. Br J Ophthalmol 1988; 72: 733-736
    CrossrefPubMedGoogle Scholar
  • 7 Sheikh A, Hurwitz B. Topical antibiotics for acute bacterial conjunctivitis: a systematic review. Br J Gen Pract 2001; 51: 473-477
    PubMedGoogle Scholar
  • 8 Everitt H, Little P. How do GPs diagnose and manage acute infective conjunctivitis? A GP survey. Fam Pract 2002; 19: 658-660
    CrossrefPubMedGoogle Scholar
  • 9 Hovding G. Acute bacterial conjunctivitis. Acta Ophthalmol 2008; 86: 5-17
    PubMedGoogle Scholar
  • 10 Rietveld RP, ter Riet G, Bindels PJ et al. Do general practitioners adhere to the guideline on infectious conjunctivitis? Results of the Second Dutch National Survey of General Practice. BMC Fam Pract 2007; 8: 54
    CrossrefPubMedGoogle Scholar
  • 11 Rose PW, Harnden A, Brueggemann AB et al. Chloramphenicol treatment for acute infective conjunctivitis in children in primary care: a randomised double-blind placebo-controlled trial. Lancet 2005; 366: 37-43
    CrossrefPubMedGoogle Scholar
  • 12 American Academy of Ophthalmology. Preferred Practice Patterns. Conjunctivitis 2008; 1-30
    PubMedGoogle Scholar
  • 13 Sheikh A, Hurwitz B. Topical antibiotics for acute bacterial conjunctivitis: Cochrane systematic review and meta-analysis update. Br J Gen Pract 2005; 55: 962-964
    PubMedGoogle Scholar
  • 14 Adebayo A, Parikh JG, McCormick SA et al. Shifting trends in in vitro antibiotic susceptibilities for common bacterial conjunctival isolates in the last decade at the New York Eye and Ear Infirmary. Graefes Arch Clin Exp Ophthalmol 2011; 249: 111-119
    CrossrefPubMedGoogle Scholar
  • 15 Asbell PA, Colby KA, Deng S et al. Ocular TRUST: nationwide antimicrobial susceptibility patterns in ocular isolates. Am J Ophthalmol 2008; 145: 951-958
    PubMed
  • 16 Cavuoto K, Zutshi D, Karp CL et al. Update on bacterial conjunctivitis in South Florida. Ophthalmology 2008; 115: 51-56
    CrossrefPubMedGoogle Scholar
  • 17 Rietveld RP, ter Riet G, Bindels PJ et al. Predicting bacterial cause in infectious conjunctivitis: cohort study on informativeness of combinations of signs and symptoms. BMJ 2004; 329: 206-210
    CrossrefPubMedGoogle Scholar
  • 18 O'Brien TP, Hahn TW. Therapy of bacterial infections of the eye. In: Duane's clinical ophthalmology. Philadelphia, Lippincott: Williams & Wilkins; 2005: 6-9
    Google Scholar
  • 19 Cvenkel B, Globocnik M. Conjunctival scrapings and impression cytology in chronic conjunctivitis. Correlation with microbiology. Eur J Ophthalmol 1997; 7: 19-23
    PubMedGoogle Scholar
  • 20 Bialasiewicz AA, Jahn GJ. Evaluation of diagnostic tools for adult chlamydial keratoconjunctivitis. Ophthalmology 1987; 94: 532-537
    PubMedGoogle Scholar
  • 21 Bobo L, Munoz B, Viscidi R et al. Diagnosis of Chlamydia trachomatis eye infection in Tanzania by polymerase chain reaction/enzyme immunoassay. Lancet 1991; 338: 847-850
    CrossrefPubMedGoogle Scholar
  • 22 Kowalski RP, Uhrin M, Karenchak LM et al. Evaluation of the polymerase chain reaction test for detecting chlamydial DNA in adult chlamydial conjunctivitis. Ophthalmology 1995; 102: 1016-1019
    PubMedGoogle Scholar
  • 23 Rietveld RP, ter Riet G, Bindels PJ et al. The treatment of acute infectious conjunctivitis with fusidic acid: a randomised controlled trial. Br J Gen Pract 2005; 55: 924-930
    PubMedGoogle Scholar
  • 24 Everitt HA, Little PS, Smith PW. A randomised controlled trial of management strategies for acute infective conjunctivitis in general practice. BMJ 2006; 333: 321
    CrossrefPubMedGoogle Scholar
  • 25 Gwon A. Topical ofloxacin compared with gentamicin in the treatment of external ocular infection. Ofloxacin Study Group. Br J Ophthalmol 1992; 76: 714-718
    CrossrefPubMedGoogle Scholar
  • 26 Horven I. Acute conjunctivitis. A comparison of fusidic acid viscous eye drops and chloramphenicol. Acta Ophthalmol (Copenh) 1993; 71: 165-168
    PubMedGoogle Scholar
  • 27 Jackson WB, Low DE, Dattani D et al. Treatment of acute bacterial conjunctivitis: 1% fusidic acid viscous drops vs. 0.3% tobramycin drops. Can J Ophthalmol 2002; 37: 228-237
    PubMedGoogle Scholar
  • 28 Leibowitz HM. Antibacterial effectiveness of ciprofloxacin 0.3% ophthalmic solution in the treatment of bacterial conjunctivitis. Am J Ophthalmol 1991; 112: 29S-33S
    PubMedGoogle Scholar
  • 29 Normann EK. Conjunctivitis in children. Lancet 2005; 366: 6-7
    CrossrefPubMedGoogle Scholar
  • 30 Abelson MB, Heller W, Shapiro AM et al. Clinical cure of bacterial conjunctivitis with azithromycin 1%: vehicle-controlled, double-masked clinical trial. Am J Ophthalmol 2008; 145: 959-965
    CrossrefPubMedGoogle Scholar
  • 31 Gibson JR. Trimethoprim-polymyxin B ophthalmic solution in the treatment of presumptive bacterial conjunctivitis – a multicentre trial of its efficacy versus neomycin-polymyxin B-gramicidin and chloramphenicol ophthalmic solutions. J Antimicrob Chemother 1983; 11: 217-221
    CrossrefPubMedGoogle Scholar
  • 32 Lancaster T, Swart AM, Jick H. Risk of serious haematological toxicity with use of chloramphenicol eye drops in a British general practice database. BMJ 1998; 316: 667
    PubMedGoogle Scholar
  • 33 Rose P. Management strategies for acute infective conjunctivitis in primary care: a systematic review. Expert Opin Pharmacother 2007; 8: 1903-1921
    CrossrefPubMedGoogle Scholar
  • 34 Golde KT, Gardiner MF. Bacterial conjunctivitis in children: a current review of pathogens and treatment. Int Ophthalmol Clin 2011; 51: 85-92
    CrossrefPubMedGoogle Scholar
  • 35 Keating GM. Levofloxacin 0.5% ophthalmic solution: a review of its use in the treatment of external ocular infections and in intraocular surgery. Drugs 2009; 69: 1267-1286
    CrossrefPubMedGoogle Scholar
  • 36 Comstock TL, Paterno MR, Usner DW et al. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% in children and adolescents with bacterial conjunctivitis: a post hoc, subgroup analysis of three randomized, double-masked, parallel-group, multicenter clinical trials. Paediatr Drugs 2010; 12: 105-112
    CrossrefPubMedGoogle Scholar
  • 37 Silver LH, Woodside AM, Montgomery DB. Clinical safety of moxifloxacin ophthalmic solution 0.5% (VIGAMOX) in pediatric and nonpediatric patients with bacterial conjunctivitis. Surv Ophthalmol 2005; 50 (Suppl. 01) 55-S63
    CrossrefPubMedGoogle Scholar
  • 38 Block SL, Hedrick J, Tyler R et al. Increasing bacterial resistance in pediatric acute conjunctivitis (1997–1998). Antimicrob Agents Chemother 2000; 44: 1650-1654
    CrossrefPubMedGoogle Scholar
  • 39 Chalita MR, Hofling-Lima AL, Paranhos Jr A et al. Shifting trends in in vitro antibiotic susceptibilities for common ocular isolates during a period of 15 years. Am J Ophthalmol 2004; 137: 43-51
    CrossrefPubMedGoogle Scholar
  • 40 Katusic D, Petricek I, Mandic Z et al. Azithromycin vs doxycycline in the treatment of inclusion conjunctivitis. Am J Ophthalmol 2003; 135: 447-451
    CrossrefPubMedGoogle Scholar
  • 41 Workowski KA, Berman S. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010; 59: 1-110
    PubMedGoogle Scholar
  • 42 Chen YM, Hu FR, Hou YC. Effect of oral azithromycin in the treatment of chlamydial conjunctivitis. Eye 2010; 24: 985-989
    CrossrefPubMedGoogle Scholar